Myriad Genetics
MYGN
262 hedge funds and large institutions have $2.62B invested in Myriad Genetics in 2019 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 88 increasing their positions, 82 reducing their positions, and 44 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
18% more capital invested
Capital invested by funds: $2.22B → $2.62B (+$400M)
5.23% more ownership
Funds ownership: 102.29% → 107.51% (+5.2%)
7% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 82
1% less funds holding
Funds holding: 264 → 262 (-2)
2% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 44
60% less call options, than puts
Call options by funds: $21.9M | Put options by funds: $54.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$46M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$28.6M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$25.1M |
| 4 |
SCM
SG Capital Management
Chicago,
Illinois
|
+$18.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19.9M |
| 2 |
Morgan Stanley
New York
|
-$15.4M |
| 3 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$11.5M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$11M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$10.8M |
MYGN Hedge Fund Activity: Q1 2019 in Review
262 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2019, worth a combined $2.62B — up 18% from $2.22B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of MYGN and 43 opened new positions — a net loss of 1 holder — while 82 trimmed existing stakes and 88 added.
The largest buyer was Disciplined Growth Investors, adding an estimated $46M. The largest seller was Vanguard Group, cutting an estimated $19.9M.
- 262 institutional investors held Myriad Genetics (MYGN) as of Q1 2019, down from 264 in Q4 2018.
- Funds reported $2.62B of Myriad Genetics stock for Q1 2019, up 18% quarter-over-quarter.
- 43 funds opened new Myriad Genetics positions in Q1 2019 and 44 closed out, a net change of -1 holder.
- The largest Myriad Genetics buyer in Q1 2019 was Disciplined Growth Investors, an estimated $46M added.
- The largest Myriad Genetics seller in Q1 2019 was Vanguard Group, an estimated $19.9M sold.
Based on aggregated 13F filings for Q1 2019.